MYSKIN DOO BEOGRAD (STARI GRAD)

Their core work

mySkin d.o.o. is a Serbian medical device startup that developed ScanZ, a digital point-of-care diagnostic tool for acne assessment. Their work centers on translating clinical dermatology workflows into a portable imaging and AI-assisted device that patients or clinicians can use without specialist infrastructure. They progressed from feasibility validation (SME Instrument Phase 1) to full product development (Phase 2), suggesting they have moved from concept to a working prototype or commercializable product. Their value proposition is reducing the time and cost of acne diagnosis by replacing subjective clinical scoring with objective digital imaging.

What they specialise in

How they've shifted over time

mySkin's H2020 history is a single product story told in two acts: a 2015 Phase 1 feasibility study with no recorded keywords, followed by a 2016–2019 Phase 2 full development project where the entire vocabulary — digital medical device, imaging device, point-of-care, e-health, m-health — emerged at once. This is not a shift in focus but a deepening of one very specific application. There is no evidence of diversification; their trajectory is pure vertical specialization in digital acne diagnostics.

They are a single-product company that has completed EU-funded development — future direction likely involves commercialization, regulatory clearance, or licensing the ScanZ technology to larger dermatology or telehealth players.

How they like to work

mySkin ran both projects as sole coordinator under the SME Instrument, which is specifically designed for single-company innovation sprints — no consortium partners appear in their record. This means they are self-reliant and do not have an established network of academic or industrial collaborators built through H2020. A potential partner should expect to be entering a relationship with a small, focused team that is used to moving fast independently rather than managing multi-partner coordination.

mySkin has zero recorded consortium partners and zero international collaborations within H2020. Their EU project history is entirely self-contained, which is typical for SME Instrument grantees but means there is no partner network to inherit through a collaboration with them.

What sets them apart

mySkin is one of very few Serbian SMEs to successfully complete both phases of the SME Instrument — Phase 1 and Phase 2 — for the same product, which signals both technical credibility and the ability to execute on a business case convincing enough for EU evaluators. Their niche is extremely specific: objective, digital, point-of-care acne assessment, which sits at the intersection of dermatology, medical imaging, and mobile health. For any consortium or company looking for a specialist in AI-assisted skin condition diagnostics from a non-EU-27 associated country, they are a rare find.

Highlights from their portfolio

• ScanZ (Phase 2)
  The largest grant (€1.6M) and the full development project — this is the main deliverable of the company's EU-funded R&D and the strongest evidence of their technical maturity.
• ScanZ (Phase 1)
  A successful SME Instrument Phase 1 feasibility study that directly led to Phase 2 funding, demonstrating a validated business case and a coherent product development path.